Drug intelligence / Profile preview

SSJG-009

Development stage: Unknown
Lead developer: Sunstar
Modality: Small Molecules
Administration: Topical

Overview

SSJG-009 is an investigational topical pharmaceutical candidate developed by Sunstar Inc. for the treatment of denture-induced oral mucosal inflammation (oral mucositis). It is designed to provide pain relief and clinical improvement in patients suffering from inflammation caused by the physical stimulation of dentures. The drug is currently being evaluated in a Phase II clinical trial in Japan, where it is administered three times daily for up to seven days to assess its efficacy and safety compared to a placebo.

Beyond the preview

Go deeper on SSJG-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSJG-009.

Explore the full profile